Ultragenyx Pharmaceutical (RARE) Lifted to Buy at Jefferies Group

Jefferies Group upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday morning, Marketbeat Ratings reports. Jefferies Group currently has $72.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $58.00. Jefferies Group also issued estimates for Ultragenyx Pharmaceutical’s FY2018 earnings at ($6.88) EPS, FY2019 earnings at ($6.43) EPS, FY2020 earnings at ($4.94) EPS and FY2021 earnings at ($2.12) EPS.

Other equities research analysts have also issued reports about the company. Stifel Nicolaus reiterated a buy rating and issued a $85.00 price objective (down from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. JMP Securities dropped their price target on Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a market outperform rating on the stock in a research report on Wednesday, August 23rd. Leerink Swann restated an outperform rating and set a $83.00 price target (down from $89.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Cowen restated an outperform rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Finally, Morgan Stanley restated an equal weight rating and set a $69.00 price target (down from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $72.40.

Shares of Ultragenyx Pharmaceutical (RARE) traded down $1.18 during mid-day trading on Monday, hitting $48.78. The stock had a trading volume of 534,000 shares, compared to its average volume of 438,441. Ultragenyx Pharmaceutical has a 12-month low of $44.02 and a 12-month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.64) earnings per share. equities research analysts anticipate that Ultragenyx Pharmaceutical will post -7.26 earnings per share for the current year.

A number of large investors have recently made changes to their positions in RARE. Sei Investments Co. bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $125,000. SG Americas Securities LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth approximately $156,000. Tocqueville Asset Management L.P. raised its holdings in shares of Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 12.0% in the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 365 shares during the period. Finally, Kazazian Asset Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth approximately $213,000. Institutional investors and hedge funds own 94.13% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3079700/ultragenyx-pharmaceutical-rare-lifted-to-buy-at-jefferies-group.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.